Clinical Trial Update: Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial comparing rivaroxaban to aspirin for non-disabling cerebrovascular events is underway; the current status is not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Drugs mentioned

• Aspirin (Aspirin)
• Xarelto (rivaroxaban)

Snippet

Sponsor: Xijing Hospital | Conditions: Ischemic Stroke, TIA | Phase 2, Phase 3 | Status: UNKNOWN